Skip to content

Effect of symbiotic supplementation in rheumatoid arthritis

Evaluation of symbiotic supplementation on the disease activity in rheumatoid arthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20121216011763N37
Enrollment
200
Registered
2019-06-25
Start date
2019-03-02
Completion date
Unknown
Last updated
2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis. Rheumatoid arthritis with rheumatoid factor

Interventions

Intervention 1: Intervention group During the 3 months of our study, we used steroid and DMARD (methotrexate) and synbiotic. This supplement made by the Lactocare brand was made by the biomarker knowl

Sponsors

the University of medical sciences Esfahan
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Rheumatoid arthritis patients (based on ACR criteria) At least 3 months after the diagnosis of RA. At least 4 swollen joints which were in a stable status for at least 1 month, on MTX and prednisolone

Exclusion criteria

Exclusion criteria: Drug reaction and hypersensitivity patient dissatisfaction consumption of probiotic oral or medical in the last 2 weeks IBD intestinal perforation creatinine clearance by using the CKD-EPI equation of less than 40 mL/min per 1.73 m2 aspartate and alanine aminotransferase levels greater than twice the upper limit of normal active or recent hepatitis or cirrhosis plan for surgery in the next 3 months thyroid disorders Cushing's disease or syndrome malignant tumors, inadequately controlled diabetes mellitus or arterial hypertension serious infections, serious cardiac or respiratory diseases, leukopenia or thrombocytopenia, inadequate contraception, pregnancy or a plan for it in the next 3 months, breastfeeding, osteoporosis, use of cytotoxic or immunosuppressive drugs for 3 months before inclusion, current or past substance abuse (including tobacco) or alcohol use greater than 2 U/d and psychological illnesses or intellectual disorders that would preclude adherence to the study protocol

Design outcomes

Primary

MeasureTime frame
Severity of disease activity. Timepoint: At the beginning of the study and 3 months after starting the drug. Method of measurement: Physical examination for the number of tender joint (T1) and swellen j (S1) and blood tests (ESR, CRP, ALT, Cr), calculate DAS28 according to ESR, Tender Joint, Sowllen joint and VAS dat.

Countries

Iran (Islamic Republic of)

Contacts

Public Contact??? ????????

Esfahan University of Medical Sciences

dr.esmaili.270288@gmail.com+98 31 3431 7469

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026